RxDoctor Payments DataLook up a doctor →

David Ramstad, MD

Internal Medicine · Suffolk, VANPI 1477516748

Payments from drug & device makers

$5,764,668in general payments, 2019–2025

Across 1,195 payments — averaging $4823.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2.4M
  • Novartis$906K
  • Pfizer$763K
  • Modernatx, Inc.$524K
  • Sanofi Pasteur Inc.$344K
  • Bavarian Nordic A/s$237K
  • plus $597K from 11 others
$650in research payments, 2019–2025

Across 1 payment — averaging $650.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$650

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen38$2,393,456
Novartis15$906,281
Pfizer92$762,510
Modernatx, Inc.403$524,001
Sanofi Pasteur Inc.26$344,265
Bavarian Nordic A/s67$237,418
Janssen Research & Development, LLC316$220,507
Kowa Research Institute, Inc.36$81,649
AstraZeneca7$76,189
Esperion Therapeutics, Inc.151$73,631
Eli Lilly4$47,876
Sanofi US Services Inc.10$42,547
GSK15$25,470
Gilead3$15,673
Regeneron2$6,325
Novo Nordisk AS1$5,000
Seqirus USA Inc9$1,872

How this compares

$5,764,668 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$67,261
Medicare patients
391
Services billed
1,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin164$199,666
OzempicSemaglutide106$115,416
TrulicityDulaglutide50$52,961
JanuviaSitagliptin Phosphate40$40,801
XareltoRivaroxaban17$27,256
RybelsusSemaglutide13$22,491
EliquisApixaban30$21,608
FarxigaDapagliflozin Propanediol11$17,657
Repatha SureclickEvolocumab16$15,145
JanumetSitagliptin Phos/Metformin Hcl22$11,578
Lantus SolostarInsulin Glargine,hum.Rec.Anlog93$9,827
Breo ElliptaFluticasone/Vilanterol16$8,996
Atorvastatin Calcium849$7,900
Tresiba Flextouch U-100Insulin Degludec13$7,385
Dexlansoprazole DrDexlansoprazole15$4,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$762,510$21,60830 claims
AstraZenecaFarxiga$76,189$17,65711 claims
GSKBreo Ellipta$25,470$8,99616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →